Compare · ARA vs DVA
ARA vs DVA
Side-by-side comparison of American Renal Associates Holdings, Inc (ARA) and DaVita Inc. (DVA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARA and DVA operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- DVA carries a market cap of $11.34B.
- DVA has hit the wire 13 times in the past 4 weeks while ARA has been quiet.
- DVA has more recent analyst coverage (14 ratings vs 0 for ARA).
- Company
- American Renal Associates Holdings, Inc
- DaVita Inc.
- Price
- -
- $177.63+0.67%
- Market cap
- -
- $11.34B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NYSE
- IPO
- 2016
- News (4w)
- 0
- 13
- Recent ratings
- 0
- 14
DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Latest ARA
- SEC Form 15-12B filed
- SEC Form EFFECT filed
- SEC Form SC 13G/A filed
- SEC Form 4 filed by P L Partners Capital Centerbridge
- SEC Form 4: W Thomas Erickson disposed to the issuer $0 worth of Common Stock (67,755 units at $0.00), decreasing ownership by 100% to 0 units
- SEC Form 4: J Christopher Hocevar disposed to the issuer $0 worth of Common Stock (18,679 units at $0.00), decreasing ownership by 100% to 0 units
- SEC Form 4: A Joseph Carlucci disposed to the issuer $0 worth of Common Stock (1,245,164 units at $0.00), decreasing ownership by 100% to 0 units
- SEC Form 4: M John Jureller disposed to the issuer $0 worth of Common Stock (49,435 units at $0.00), decreasing ownership by 100% to 0 units
- SEC Form 4: T Syed Kamal disposed to the issuer $0 worth of Common Stock (1,291,236 units at $0.00), decreasing ownership by 100% to 0 units
- SEC Form 4: Victoria Labriola disposed to the issuer $0 worth of Common Stock (64,569 units at $0.00), decreasing ownership by 100% to 0 units
Latest DVA
- DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease
- Director Hollar Jason M. was granted 278 shares, increasing direct ownership by 4% to 6,883 units (SEC Form 4)
- Director Desoer Barbara J was granted 278 shares (SEC Form 4)
- Director Pullin Dennis W was granted 278 shares, increasing direct ownership by 10% to 2,949 units (SEC Form 4)
- Director Moore Gregory J. was granted 278 shares, increasing direct ownership by 4% to 8,091 units (SEC Form 4)
- Director Yale Phyllis R was granted 278 shares, increasing direct ownership by 3% to 9,803 units (SEC Form 4)
- Director Schechter Adam H was granted 278 shares, increasing direct ownership by 5% to 5,970 units (SEC Form 4)
- Director Schoppert Wendy Lee was granted 278 shares (SEC Form 4)
- Director Arway Pamela M was granted 278 shares, increasing direct ownership by 1% to 27,223 units (SEC Form 4)
- DaVita upgraded by TD Cowen with a new price target